1. Introduction

Satisfactory post-surgical recovery is reflected in a reduction in plasma levels of pro-inflammatory and anti-inflammatory cytokines, which are higher in septic and surgery patients than in healthy individuals [1-4]. The persistence of inflammatory cytokines in the circulation indicates a generalized systemic inflammatory response and is associated with Multiple-Organ Dysfunction Syndrome (MODS) and death in critically ill patients [5].

In the systemic inflammatory response, inflammation and coagulation can be stimulated by microbial invasion (exogenous injury) or direct tissue injury (endogenous injury), when the NF-kB protein translocates into the nucleus and activates the transcription of both proinflammatory (e.g. IL-6) and anti-inflammatory (e.g. IL-10) cytokines [6].

In the course of an inflammatory process, endothelial cells and polymorphonuclear leukocytes (PMNs) generate elevated amounts of reactive oxygen species (ROS) [7], which act as secondary mediators, inducing chemotactic substances (e.g. cytokines) and adhesion molecules that amplify the inflammatory process. Vitamin C is a hydrophilic antioxidant molecule that acts as ROS scavenger and vitamin E regenerator [8] and has been shown to reduce cytokine production in different assays [9-12].

The microcirculation is particularly susceptible to oxidative stress which leads to the systemic inflammatory response syndrome, hemodynamic instability, and multiple organ failure [13]. Vitamin C plasma concentrations are strongly altered in patients with sepsis [14]. Restoring antioxidant and endothelial functions in the critically ill patient requires supraphysiologic concentrations of ascorbate [15]. Such concentrations can only be achieved by parenteral administration. In a trial in 14 patients, 2 days on 3000 mg/d given
intravenously were required in critically ill patients to obtain a significant increase of plasma ascorbate concentrations [16]. The rapid replenishment of ascorbate is of special clinical significance in critically ill patients because these patients experience drastic reductions in ascorbate concentrations, and this may be a causal factor in the development of circulatory shock [17]. In a randomized controlled antioxidant trial including 200 patients in the ICU and providing a combination of selenium, zinc, vitamin C, and vitamin B1, it was shown no survival benefit, but antioxidants shortened hospital stay in surviving trauma patients [18]. In a retrospective trial involving 4294 patients, of whom 2272 received antioxidants for 7 days, resulted in a 28% relative risk reduction in mortality and a significant reduction in both hospital and ICU length of stay [19].

The rationale for a benefit in this category of patients with requirements for major wound healing is strong and is reinforced by the beneficial effects shown in the trials that included vitamin C. The optimal duration of supplementation has not yet been determined, but benefits appear after 5 days of supplementation. On the basis of the pharmacokinetic aspects of antioxidants, an intravenous dose ranging between 1 and 3 g/d should probably be considered independent of parenteral nutrition doses in patients with major trauma at least during the first week after injury [17].

Cytokines exert a key role in inflammatory host defense, therefore the study of their levels and their pharmacological modulation is of great interest for the management of septic patients who underwent abdominal surgery.

2. Patients and methods

2.1. Study design and patients: A prospective, pilot study was performed in 20 consecutive septic abdominal surgery patients in our Digestive Surgery Department with postoperative mortality risk of >30 % by POSSUM score [20]. POSSUM was selected to predict death rate more accurately compared to the APACHE II classification [21]. In all cases, sepsis was produced by peritoneal infection. Patient characteristics are listed in Table 1. Ten healthy volunteers were recruited as a control group. Written informed consent was obtained from all patients or their relatives, and the study was approved by the local Clinical Research Ethics Committee. Allocation of patients to experimental (n=10) or placebo (n=10) group was by envelope randomization (designed by a statistician).

2.2. Treatments: Experimental and placebo treatments were started at 12 h post-surgery. Treatments were administered daily on 6 consecutive postoperative days. The experimental (vitamin C) group received 450 mg/day of the vitamin in 5% dextrose administered in three equal doses, and the placebo group received an identical administration of 5% dextrose following previous studies [22,23]. Placebo-treated patients received no supplemental nutrition containing vitamins nor vitamin C.

2.2. Samples: Early-morning peripheral blood samples were drawn for 7-9 a.m. by venipuncture from all patients on every treatment day into a 3-ml sterile EDTA tube. They were immediately centrifuged at room temperature (400 x g for 16 min), and the
supernatant (plasma) was taken for cytokine determination. Sample collection started at 24 h after vitamin C/placebo administration (T1d) and lasted for 6 days (T1d, T2d, T3d, T4d, T5d and T6d).

2.4. Measurements: Plasma IL-6 concentrations were determined in a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA) using the BD Cytometric Bead Array (CBA) (Becton Dickinson, San Jose, CA, USA). The CBA technique employs a series of particles with discrete fluorescence intensities to simultaneously detect soluble analytes [24]. The BD CBA system uses the sensitivity of amplified fluorescence detection by flow cytometry to measure soluble analytes in a particle-based immunoassay. Each bead in a BD CBA provides a capture surface for a specific protein and is analogous to an individually coated well in an ELISA plate. The sensitivity of the BD CBA system was 3.0 pg/ml for IL-6.

2.5. Statistical analysis: A two-way analysis of variance was performed between quantitative independent variables (plasma cytokine concentrations) and qualitative dependent variables (placebo/Vitamin C treatment). Because of the small number of patients in each treatment group, a non-parametric test (U Mann-Whitney) was applied to compare differences between the treatment groups and between these groups and the healthy controls. *P*<0.05 was considered significant. Data are presented as mean values ± standard error (SE).

3. Results

General characteristics of patients are listed in Table 1. Four (40%) of the ten patients in each group (vitamin C and placebo) developed MODS during the 6 days postoperative period studied. At the end of this period, the postoperative mortality rate was 40% in the placebo group and 60% in the vitamin C group.

Plasma IL-6 concentrations were significantly reduced in experimental group, which received vitamin C, compared with the placebo group during most of the postoperative period, reaching a significant difference on day 2 and day 6 (*p*=0.048 and *p*=0.033) (Figure 1). Table 2 shows IL-6 values during 6the period of study.

|                         | PLACEDO (n=10) | Vitamin C (n=10) |
|-------------------------|----------------|-----------------|
| Age (years)             | 65.1 ± 3.6     | 67.8 ± 4.5      |
| Mortality risk: %       | 52.0 ± 4.1     | 60.5 ± 8.7      |
| POSSUM: Score           | 50.4 ± 1.4     | 55.0 ± 3.3      |
| Sex (Men/Women)         | 6/4            | 5/5             |
| Diagnoses               |                |                 |
| Peritonitis (perforations or inflammations of gallbladder, colon, biliary or cholecystitis and ulcers) | 6 | 7 |
| Complicated intestinal ischemia | 1 | 1 |
| Intra-abdominal abscesses | 1           | 1               |
| Anastomotic leakage after gastrectomy | 1 | 0 |
| Cholangitis             | 1              | 1               |
Table 1. General characteristics, diagnoses and surgical procedures of abdominal surgery patients studied. Data are presented as mean values ± standard error of mean (SEM).

| Surgical Procedure                                      | Count | Count |
|--------------------------------------------------------|-------|-------|
| Intestinal resection with or without anastomosis        | 5     | 3     |
| Perforation suture                                      | 3     | 3     |
| Collection drainage or anastomosis dehiscence           | 1     | 1     |
| Cholecystectomy with or without drainage of biliary tract | 1     | 3     |
| Pressors                                               | 2/10  | 3/10  |
| Ventilatory support                                    | 2/10  | 3/10  |

Oxygenation Parameters

| Parameter   | Mean ± Standard Error | Mean ± Standard Error |
|-------------|-----------------------|-----------------------|
| PO₂ (mmHg)  | 144.7 ± 47.3          | 113.9 ± 50.5          |
| PCO₂ (mmHg) | 47.2 ± 7.4            | 45.7 ± 7.7            |

Creatinine (mg/dl)

| Creatinine (mg/dl) | 1.99 ± 0.21 | 2.15 ± 0.12 |

Lactate (meq/L)

| Lactate (meq/L) | 1.97 ± 0.55 | 3.22 ± 1.25 |

Volume Status (based on the blood sodium level in mmol/L)

| Volume Status | 137.42 ± 7.19 | 138.07 ± 6.11 |

Figure 1. Time course of plasma IL-6 levels (pg/ml) in vitamin C and placebo-treated surgical patients. Statistically significant differences are marked with asterisk (T2d: p=0.048, T6d: p=0.033).
**Table 2.** IL-6 values (pg/ml) in placebo and vitamin C groups.

| Cytokine | Healthy Control | Placebo | T1d   | T2d   | T3d   | T4d   | T5d   | T6d   |
|----------|-----------------|---------|-------|-------|-------|-------|-------|-------|
| IL-6 (pg/ml) | 9.7 ± 2.4       |         | 350.5 ± 92.6 | 237.5 ± 82.3 | 219.3 ± 13.2 | 296.3 ± 78.5 | 248.9 ± 159.6 | 359.7 ± 99.9 |
|          |                | Vit. C  | 502.3 ± 161.3 | 136.4 ± 59.3 | 171.4 ± 95.5 | 132.5 ± 85.8 | 63.0 ± 34.2 | 57.1 ± 36.2 |

**4. Discussion**

Plasma IL-6 high concentrations have been documented in high-risk septic abdominal surgery patients [1, 25, 26]. Elevated plasma cytokine levels derive from severe inflammatory processes caused by the disease resulting in an excess of inflammatory mediators. Taking into account the severity of the inflammatory process, plasma cytokine levels have been related to post-surgical complications [4, 25, 26, 27], organ dysfunction development [5, 25, 28, 29] and mortality in critical care, surgery, sepsis and SIRS [1, 3, 29, 30-35]. These events are related to the pro-inflammatory environment that predominates in sepsis, which is responsible for the overactivation of leukocytes and endothelial cells associated with tissue injury. Elevated levels of pro-inflammatory cytokines, notably IL-6, produce early PMN priming and sequestration and are potential mediators of early tissue damage [36,37], exacerbating systemic inflammation through the chronic release of toxic products at inflammation sites [38]. The results presented in our study in patients who underwent abdominal surgery, demonstrate that vitamin C has an inhibitory effect on plasma cytokine concentrations, finding lower IL-6 levels in the vitamin-treated versus placebo-treated patients that reached significance after 2 days and 6 days of treatment. These observations are according with those previously reported for in vitro studies by Härtel et al [9] and Bergman et al [10], in studies describing the effect of vitamin C on the intracytoplasmic production of pro-inflammatory cytokines in whole blood samples of healthy individuals, and in vivo by Fischer et al [11] reporting that supplementation with antioxidants in healthy volunteers inhibited the IL-6 release from the contracting human skeletal muscle.

The results showed in the present report contribute to clarify the optimal duration of supplementation and reinforce the concept that benefits appear after 5 days of supplementation such as has been noted previously [17].

This inhibitory effect of vitamin C on cytokine production may result from a reduction in the production of ROS, which are at least in part responsible for excessive cytokine production by promoting cell overproduction or by modulating nuclear factors such as NF-kβ, which is involved in cytokine synthesis [7]. The present findings suggest that ROS clearance by scavengers, such as vitamin C, attenuates plasma levels of IL-6, one of the main pro-inflammatory mediators in the acute inflammatory processes observed in septic patients who underwent abdominal surgery and other critically ill patients. A reduction in plasma IL-6 concentrations may improve the prognosis in patients with postoperative persistence of elevated pro-inflammatory mediators, and has been defined as the best parameter for predicting development of MODS as compared to other cytokines [38].
Although different surgical approaches were used in these patients, according to the decision of the surgeons in charge, we emphasize that all patients had a clinical picture of severe peritonitis and a POSSUM score > 50 points. In our view, the differences in surgical procedure would not have influenced results, although a study of a larger sample of patients is warranted to confirm these results.

In conclusion, further studies in larger patient samples are required to establish whether this pharmacological intervention enhances post-surgery recovery, preventing complications and MODS in septic patients who underwent abdominal surgery.

5. Conclusion

Septic patients who underwent abdominal surgery treated with vitamin C for 6 days post-surgery showed a significant reduction in plasma IL-6 levels, which may benefit these patients by downregulating their enhanced systemic pro-inflammatory response.

Author details

Ignacio Ferrón-Celma, Carmen Olmedo and Pablo Bueno
Experimental Surgery Research Unit, Virgen de las Nieves University Hospital, Granada, Spain

Alfonso Mansilla, Ana García-Navarro, Karim Muffak and Jose-Antonio Ferrón
General and Digestive Surgery Department, Virgen de las Nieves University Hospital, Granada, Spain

Acknowledgement

The authors thank the surgeons and nurses of the General and Digestive Surgery Department and the personnel of the Emergency and Critical Care Department of Virgen de las Nieves University Hospital (Granada, Spain) for their help in patient recruitment and blood sampling. The contribution of pharmacists from the Pharmacy Department of Virgen de las Nieves University Hospital is gratefully acknowledged, as is the excellent technical assistance of the staff of the Experimental Surgery Research Unit and statisticians from the FIBAO foundation.

6. References

[1] Torre D, Tambini R, Aristodemo S, Gavazzeni G, Goglio A, Cantamessa C, Pugliese A, Biondi G. Anti-inflammatory response of IL-4, IL-10 and TGF-beta in patients with systemic inflammatory response syndrome. Mediators Inflamm 2000; 9: 193-5.
[2] Munster AM. Gut: Clinical importance of bacterial translocation, permeability, and other factors. In: Baue AE, Faist E, Fry DE, editors. Multiple Organ Failure: Pathophysiology, prevention and therapy. New York: Springer; 2000. p. 86-1.
[3] Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119: 771-8.
[4] Miyaoka K, Iwase M, Suzuki R, Kondo G, Watanabe H, Ito D, et al. Clinical evaluation of circulating interleukin-6 and interleukin-10 levels after surgery-induced inflammation. J Surg Res 2005; 125: 144-50.

[5] Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993; 103: 565-75.

[6] Colmes CL, Russell JA, Walley KB. Genetic polymorphisms in sepsis and septic shock. Chest 2003; 124:1103-15.

[7] Closa D, Folch-Puy E. Oxygen free radicals and the systemic inflammatory response. IUBMB Life. 2004; 56: 185-91.

[8] Goode HF, Webster NR. Free radicals and antioxidants in sepsis. Crit. Care Med. 1993; 21: 1770-6.

[9] HärTEL C, Strunk T, Bucsky P, Schultz C. Effects of vitamin C on intracytoplasmic cytokine production in human whole blood monocytes and lymphocytes. Cytokine 2004; 27: 101-6.

[10] Bergman M, Salmon H, Djaldetti M, Fish L, Punsly I, Bessler H. In vitro immune response of human peripheral blood cells to vitamins C and E. J Nutr Biochem 2004; 15: 45-50.

[11] Fischer CP, Hiscock NJ, Penkowa M, Basu S, Vessby B, Kallner A, et al. Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle. J Physiol 2004; 558: 633-45.

[12] Vassilakopoulos T, Karatza MH, Katsaounou P, Kollintza A, Zakynthinos S, Roussos C. Antioxidants attenuate the plasma cytokine response to exercise in humans. J Appl Physiol 2003; 94: 1025-32.

[13] Biesalski HK, McGregor GP. Antioxidant therapy in critical care – is the microcirculation the primary target? Crit Care Med 2007; 35(Suppl):S577–S583.

[14] Galley HF, Davies MJ, Webster NR. Ascorbyl radical formation in patients with sepsis: effect of ascorbate loading. Free Radic Biol Med 1996;20:139–143.

[15] McGregor GP, Biesalski HK. Rationale and impact of vitamin C in clinical nutrition. Curr Opin Clin Nutr Metab Care 2006;9:697–703.

[16] Long CL, Maull KI, Krishnan RS, et al. Ascorbic acid dynamics in the seriously ill and injured. J Surg Res 2003;109:144–148.

[17] Berger MM. Vitamin C Requirements in Parenteral Nutrition. Gastroenterology 2009; 137: S70-S78.

[18] Berger MM, Soguel L, Shenkin A, et al. Influence of early antioxidant supplements on clinical evolution and organ function in critically ill cardiac surgery, major trauma and subarachnoid hemorrhage patients. Crit Care 2008;12:R101.

[19] Collier BR, Giladi A, Dossett LA, Dyer L, Fleming SB, Cotton BA. Impact of high-dose antioxidants on outcomes in acutely injured patients. J Parenter Enteral Nutr 2008; 32:384–388.

[20] Copeland GP, Jones D, Walters M. POSSUM: a scoring system for surgical audit. Br J Surg 1991; 78: 355-60.

[21] Crea N, Di Fabio F, Pata G, Nascimbeni R. APACHE II, POSSUM, and ASA scores and the risk of perioperative complications in patients with colorectal disease. Ann Ital Chir. 2009; 80(3): 177-81.

[22] Clemens MR, Waladkhani AR, Bublitz K, Ehninger G, Gey KF. Supplementation with antioxidants prior to bone marrow transplantation. Wien Klin Wochenschr 1997; 109: 771-6.
[23] Ferrón-Celma I., Mansilla A., Hassan L., García-Navarro A., Comino A.M., Bueno P., Ferrón J.A. Effect of vitamin C administration on neutrophil apoptosis in septic patients after abdominal surgery. Journal of Surgical Research 2009; 153:2: 224-230.

[24] Cook EB, Stahl JL, Lowe L, Chen R, Morgan E, Wilson J, et al. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J Immunol Methods 2001; 254: 109-18.

[25] Davis MG, Hagen PO. Systemic inflammatory response syndrome. Br J Surg 1997; 84: 929-35.

[26] Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamura M. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine 2005; 29: 169-175.

[27] Mokart D, Capo C, Blache JL, Delpero JR, Houvenaeghel G, Martin C, et al. Early postoperative compensatory anti-inflammatory response syndrome is associated with septic complications after major surgical trauma in patients with cancer. Br J Surg 2002; 89: 1450-6.

[28] Mokart D, Merlin M, Sannini A, Brun JP, Delpero JR, Houvenaeghel G, et al. Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major surgery. Br J Anaesth 2005; 94: 767-73.

[29] Friedman G, Jankowski S, Marchant A, Goldman M, Kahn RJ, Vincent JL. Blood interleukin 10 levels parallel the severity of septic shock. J Crit Care 1997; 12: 183-7.

[30] Roumen RM, Hendriks T, van der Ven-Jongekrijg J, Nieuwenhuijzen GA, Sauverwein RW, van der Meer JW, et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993; 218: 769-76.

[31] Van der Poll T, de Waal Malefyt R, Coyle SM, Lowry SF. Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 1997; 175: 118-22.

[32] Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1: 355-7.

[33] Grau GE, Taylor TE, Molyneux ME, Wirima JJ, Vassalli P, Hommel M, et al. Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med 1989; 320: 1586-91.

[34] Debets JM, Kampmeijer R, van der Linden MP, Buurman WA, van der Linden CJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989; 17: 489-94.

[35] Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74: 1704-10.

[36] Botha AJ, Moore FA, Moore EE, Kim FJ, Banerjee A, Peterson VM, et al. Postinjury neutrophil priming and activation: an early vulnerable window. Surgery 1995; 118: 358-64.

[37] Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa A. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med 1999; 27: 1262-4.

[38] Frink M, Van Griensven M, Kobbe P, Brin T, Zeckey C, Vaske B, Krettek C, Hildebrand F. IL-6 predicts organ dysfunction and mortality in patients with multiple injuries. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2009; 17:49 doi:10.1186/1757-7241-17-49